204: Changing the Course of Disease in Lupus

Monday, October 31, 2022

10:00 AM – 10:05 AM Eastern Time

All of the relevant financial relationships listed for faculty have been mitigated.

Industry Presenter(s)

AA

Anca Askanase, MD, MPH

Director
Columbia University Medical Center
New York, NY, United States

Disclosure(s): Amgen: Advisor or Review Panel Member (Ongoing); AstraZeneca: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing); Aurinia: Advisor or Review Panel Member (Ongoing); Eli Lilly: Grant/Research Support (Ongoing); GlaxoSmithKlein(GSK): Advisor or Review Panel Member (Ongoing); Idorsia: Grant/Research Support (Ongoing); Janssen: Grant/Research Support (Ongoing); Pfizer: Grant/Research Support (Ongoing); UCB: Grant/Research Support (Ongoing)
RR

Rajeev Raghavan, MD, FASN

Director
HCA Kingwood Internal Medicine Residency
Kingwood, TX, United States

Disclosure information not submitted.

This session Introduces disease modification in the treatment of SLE and discuss how modifying the underlying disease may result in lower disease activity and improved disease outcomes.

Developed and offered by GSK